Bayer announced Wednesday that it has recorded positive results with its Nubeqa in the treatment of hormone-sensitive metastatic prostate cancer (mHSPC).

The German group reports that a Phase III study showed that the combination of Nubeqa and antiandrogen therapy (TAA) met its primary endpoint of progression-free radiological survival.

In a press release, Bayer explains that it plans to submit these data to the U.S. Food and Drug Administration (FDA) for approval in the near future.

Nubeqa is already approved in over 70 markets worldwide, including the US, Europe, Japan and China, for the treatment of non-metastatic castration-resistant prostate cancer (mCRPC).

The compound - jointly developed with Orion of Finland - is also being studied in patients at various stages of prostate cancer.

Following this announcement, Bayer shares were down 0.3% on Wednesday morning on the Paris Bourse.

Copyright (c) 2024 CercleFinance.com. All rights reserved.